Literature DB >> 21623185

Immunohistochemical determination of ETS-1 oncoprotein expression in urothelial carcinomas of the urinary bladder.

Aysegul Sari1, Aylin Calli, Sacit Nuri Gorgel, Aysegul Aksoy Altinboga, Cengiz Kara, Cetin Dincel, Fulya Cakalagaoglu.   

Abstract

ETS-1 protooncogene is an important transcription factor that plays a role in the regulation of physiological processes, such as cell proliferation and differentiation. ETS-1 is thought to be related to the growth of carcinoma cells by its regulation of the transcription of matrix metalloproteinases and urokinase-type plasminogen activator. In this study, we aimed to investigate the expression pattern of ETS-1 oncoprotein in urothelial carcinomas of the urinary bladder and determine its relationship with histopathologic parameters, including tumor grade and stage. One hundred six specimens of urothelial carcinoma and a total of 14 normal urothelium were analyzed immunohistochemically with anti-ETS-1 monoclonal antibody. The normal urothelium showed positive ETS-1 immunostaining. ETS-1 expression remained high in low-grade and noninvasive tumors, whereas it frequently decreased in high-grade or invasive carcinomas. Interestingly, ETS-1 was highly expressed in the basal cell layer of the noninvasive urothelial carcinomas. ETS-1 expression showed a strong negative correlation with the tumor grade (P<0.001; r, -0.67) and stage (P<0.001; r, -0.75). The nonmuscle-invasive tumors (pTa+pT1) and noninvasive tumors (pTa) had significantly higher ETS-1 expression than the muscle-invasive tumors (pT2; P<0.001) and invasive tumors (pT1+pT2; P<0.001), respectively. Results of our study show that decreased ETS-1 expression is significantly associated with high grade and advanced stage in urothelial carcinomas of the urinary bladder, and that the downregulation of ETS-1 expression may be a marker of the aggressiveness of such malignancies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21623185     DOI: 10.1097/PAI.0b013e31821ba035

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  4 in total

Review 1.  Review of Ets1 structure, function, and roles in immunity.

Authors:  Lee Ann Garrett-Sinha
Journal:  Cell Mol Life Sci       Date:  2013-01-05       Impact factor: 9.261

2.  Novel variants in MLL confer to bladder cancer recurrence identified by whole-exome sequencing.

Authors:  Song Wu; Zhao Yang; Rui Ye; Dan An; Chong Li; Yitian Wang; Yongqiang Wang; Yi Huang; Huan Liu; Feida Li; Luyun He; Da Sun; Yuan Yu; Qiaoling Li; Peide Huang; Meng Zhang; Xin Zhao; Tengteng Bi; Xuehan Zhuang; Liyan Zhang; Jingxiao Lu; Xiaojuan Sun; Fangjian Zhou; Chunxiao Liu; Guosheng Yang; Yong Hou; Zusen Fan; Zhiming Cai
Journal:  Oncotarget       Date:  2016-01-19

3.  Inhibiting cell migration and cell invasion by silencing the transcription factor ETS-1 in human bladder cancer.

Authors:  Li Liu; Yuchen Liu; Xintao Zhang; Mingwei Chen; Hanwei Wu; Muqi Lin; Yonghao Zhan; Chengle Zhuang; Junhao Lin; Jianfa Li; Wen Xu; Xing Fu; Qiaoxia Zhang; Xiaojuan Sun; Guoping Zhao; Weiren Huang
Journal:  Oncotarget       Date:  2016-05-03

4.  Synthetic Bax-Anti Bcl2 combination module actuated by super artificial hTERT promoter selectively inhibits malignant phenotypes of bladder cancer.

Authors:  Li Liu; Yuchen Liu; Tianbiao Zhang; Hanwei Wu; Muqi Lin; Chaoliang Wang; Yonghao Zhan; Qing Zhou; Baoping Qiao; Xiaojuan Sun; Qiaoxia Zhang; Xiaoqiang Guo; Guoping Zhao; Weixing Zhang; Weiren Huang
Journal:  J Exp Clin Cancer Res       Date:  2016-01-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.